Results 21 to 30 of about 30,227 (301)
THE EFFECT OF BROMOCRIPTINE ON C-REACTIVE PROTEIN IN WOMEN WITH HYPERPROLACTINEMIC AMENORRHEA [PDF]
The Medical Journal of Basrah University, 2008 C-reactive protein has become the subject of avid interest in recent years. Increased concentrations of C-reactive protein (CRP) became widely accepted as a risk factor of many inflammatory diseases including atherosclerosis, ischemic vascular diseases ...
Isam Hamo Mahmood
doaj +1 more source
BMC Endocrine Disorders, 2020 Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr +6 more
doaj +1 more source
Study on antihyperglycemic effect of bromocriptine in dexamethasone induced hyperglycemic wistar rats [PDF]
, 2021 Background: Diabetes mellitus is a chronic metabolic disorder that develops due to insulin deficiency or insulin resistance. Recent animal and human studies have reported bromocriptine to be effective in the management of type 2 diabetes mellitus.
Bhandare, Basavaraj +3 more
core +2 more sources
Bromocriptine in Parkinsonism. [PDF]
BMJ, 1978 A review of the effects of using bromocriptine in Parkinson's disease showed that it rarely helps patients not primarily improved by levodopa. Patients who show late failure with levadopa and whose response to treatment is declining are helped by combining the two drugs.
John Pearce, Iris Pearce
openaire +3 more sources
Journal of Diabetes Investigation, 2021 Dopamine receptor agonists are typically used to treat Parkinson’s disease and certain pituitary tumors, such as prolactinoma or a growth hormone‐producing tumor.
Motoyuki Igata +8 more
doaj +1 more source
Discriminating depression, physical and social anhedonia by neurotransmitter related challenge tests [PDF]
, 2016 The aim of this study was to investigate, if anhedonia, a salient component of depression, shows similar response patterns to neurotransmitter challenge tests as depression, and if the two questionnaire based components Physical (PA) and Social (SA ...
Hennig, Juergen, Netter, Petra
core +2 more sources
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study
European Heart Journal, 2017 Aims An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM.
D. Hilfiker-Kleiner +20 more
semanticscholar +1 more source
Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis
Cancer Cell International, 2007 Background Prolactinoma is the most frequent pituitary tumor in humans. The dopamine D2 receptor agonist bromocriptine has been widely used clinically to treat human breast tumor and prolactinoma through inhibition of hyperprolactinemia and induction of ...
Huang Mu-Chiou +7 more
doaj +1 more source
Diabetology & Metabolic Syndrome, 2023 Background Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk.
Mulualem Tesfaye Birhan +3 more
doaj +1 more source
Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
American Journal of Perinatology Reports, 2018 Objective This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy.
Rebecca Simon +2 more
doaj +1 more source